Screener
Dyne Therapeutics, Inc. DYN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $100,889 | $106,447 |
| General and administrative | 24,387 | 15,925 |
| Total operating expenses | 125,276 | 122,372 |
| Loss from operations | (125,276) | (122,372) |
| Other income (expense): | ||
| Interest income | 8,757 | 7,100 |
| Interest expense | (4,202) | — |
| Other expense, net | (133) | (89) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s operating income?
- Dyne Therapeutics, Inc. (DYN) reported operating income of -$125.28M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s operating income changed year-over-year?
- Dyne Therapeutics, Inc.'s operating income decreased by 2.4% year-over-year, from -$122.37M to -$125.28M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s operating income has grown at a 32.9% compound annual growth rate (CAGR), from -$150.03M to -$468.18M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Dyne Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude